Aligos Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Unregistered sales of equity securities
In October 2023, the Company completed a PIPE offering and entered into the Securities Purchase Agreement with certain institutional and accredited investors, pursuant to which the Company agreed to offer, issue and sell to these investors 31,429,266 shares of Common Stock, 81,054,686 Pre-Funded Warrants, and 56,241,973 Common Warrants. Each Pre-Funded Warrant has an exercise price of $0.0001 per share of common stock, was immediately exercisable and is exercisable until exercised in full. Each accompanying Common Warrant has an exercise price of $0.7568 per share of common stock, is immediately exercisable and will expire on October 25, 2030. Each warrant is exercisable for one share of Common Stock.
In April 2024 an investor exercised 2,441,406 Pre-Funded Warrants for an aggregate purchase price of $244.14 and was issued 2,441,406 shares of Common Stock.
In February 2024 an investor exercised 569,125 Pre-Funded Warrants for an aggregate purchase price of $56.91 and was issued 569,125 shares of Common Stock.
Use of proceeds
None.
Issuer purchasers of equity securities
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.